CLGN
CollPlant Biotechnologies Ltd. (CLGN) Economic Moat Analysis (2026)
Overall Score
Pricing Power
Gross margin remains deeply negative at -319.3% TTM, indicating no evidence of pricing power.
Revenue per share is only 0.28 TTM while price-to-sales is 12.0, suggesting the market is valuing sales despite weak monetization.
Cost Advantage
Operating margin is -33.3% TTM and EBITDA margin is -30.9% TTM, showing the company is still structurally unprofitable.
R&D and SG&A remain heavy relative to revenue at 19.9% and 10.1% TTM, limiting any sign of scale-based cost leverage.
Switching Costs
No evidence of customer lock-in or recurring revenue durability is visible in the financials.
The very high cash conversion cycle of 228.5 days suggests weak operating efficiency rather than sticky customer relationships.
Network Effects
There is no financial evidence of network-driven monetization or user flywheel effects.
Negative profitability and low asset turnover do not support a self-reinforcing ecosystem.
Intangible Assets
R&D intensity is high at 19.9% of revenue, but the financials do not yet show durable commercialization benefits.
Intangibles are only 0.6% of total assets, so the balance sheet does not indicate a moat built on acquired IP or brand assets.
Efficient Scale
Asset turnover is just 0.04 and fixed-asset turnover is 0.11, pointing to a business that is not yet operating at efficient scale.
The company’s small market cap and persistent losses suggest limited scale advantages versus larger competitors.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on CollPlant Biotechnologies Ltd.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

